HUTCHMED (00013): Regulatory submissions for ORPATHYS in combination with TAGRISSO for the treatment of MET-driven EGFR-mutated lung cancer accepted in Europe and Japan

Zhitong Finance APP news, Hutchmed (00013) announced that the regulatory registration applications for the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) have been accepted in Europe and Japan.